Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diagnos Laboratorium Utama Tbk. (DGNS) vs Reksa Dana Indeks Batavia IDX30 ETF (XBID) Price & Performance

Diagnos Laboratorium Utama Tbk.Trade
Reksa Dana Indeks Batavia IDX30 ETFTrade

Price performance (Past 24H)

Key statistics

Diagnos Laboratorium Utama Tbk. vs Reksa Dana Indeks Batavia IDX30 ETF — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp228 (market cap 319B, 8.7K 24h volume), while Reksa Dana Indeks Batavia IDX30 ETF trades at Rp457 (market cap 15.84B, 51.8K 24h volume). The key difference: Diagnos Laboratorium Utama Tbk. is far larger — about 20.1× Reksa Dana Indeks Batavia IDX30 ETF's market cap, and Reksa Dana Indeks Batavia IDX30 ETF is more actively traded (51.8K versus 8.7K). Which is the better fit depends on your goals.

DGNSXBID
Market Cap
319B15.84B
Volume
8.7K51.8K
Lot
87518
Turnover
1.99M22.68M
Average Price
229.29437.87
Value
1.99M22.68M
Indicative Equilibrium Price
232
Indicative Equilibrium Volume
200

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DGNS
View details

About Diagnos Laboratorium Utama Tbk.

PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.

Read more on DGNS

About Reksa Dana Indeks Batavia IDX30 ETF

Read more on XBID